It was a fun experience at the @PGShowcases #JrNational Showcase in Georgia! Hit a stand up oppo double during game play. Thank you @pg_int1 @PerfectGameUSA PGTV @JeredGoodwin3 @PG_Uncommitted @TorontoMets @CPBLeague @richleitch47 @OBC_Recruits @CDNBaseballNet @BlueJaysAcademy

Great job this weekend @RoShowBaseball keep working hard 💪 we’re very proud of how far you’ve come & looking forward to more great baseball ⚾️ @TorontoMets

‘28 Rohan Persad (ON-CAN) @pg_int1 #JrNational

"Grateful, but I don't like any of it." I asked Bassitt about the standing ovation he got from the Blue Jays' crowd yesterday. Covering Cbass for his years in Toronto, I know he doesn't like a fuss made about him, but if you don't, Bassit hates getting attention: @6ixinningpod

#ASCO26 This one is special. This is the hottest paper of 2026 and potentially in the history of pancreatic cancer. Let’s dive in. RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer Abstract LBA5 (soon!) Presentation: May 31, 2026, 3:21-3:33 PM CDT For decades, pancreatic cancer has been where good ideas go to die. We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains. But the central driver of PDAC has always been sitting there in plain sight: RAS. More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it. Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS. And in RASolute 302, it delivered. Quick hits: 📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy 🧬 RAS G12 population 91.8% of patients had RAS G12 mutations 📈 OS in RAS G12 population 13.2 vs 6.6 months HR 0.40 P<0.001 📈 OS in overall population 13.2 vs 6.7 months HR 0.40 P<0.001 📊 PFS in RAS G12 population 7.3 vs 3.5 months HR 0.45 P<0.001 📊 PFS in overall population 7.2 vs 3.6 months HR 0.49 P<0.001 🔥 12-month OS Overall population: 53.2% vs 17.3% ⚠️ Toxicity matters, but this was not just more efficacy for more toxicity Grade ≥3 AEs: 61.8% vs 69.6% TRAEs leading to discontinuation: 1.2% vs 11.2% This is the kind of survival curve we almost never get to see in pancreatic cancer. This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial. The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone. RAS is here, and it couldn’t have come sooner. nejm.org/doi/full/10.1056/NE… @TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO @NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

1/ the @NHS-Galleri trial is 1st RCT for molecular screening for early cancer detection. 142K participants; found ~1400 cancers overall (i.e. 1% ). No sig reduction in incidence rates of stage III/IV cancers. No change in rate @ prevalent vs incident rds.

RT @WeBelieveEM: Carter Hart is about to play in the Stanley Cup Final. He was acquitted of sexual assault charges this past summer, but th…

Sunny vibes this Mother’s Day, started the day with a nice run @UofT campus and now @TorontoMets baseball with @RoShowBaseball. After games cancelled for rain yest, the baseball Gods must be moms! ☺️💕

Got the start for @TorontoMets @CPBLeague 3.0 IP 7 Ks 0 ER. Looking forward to the next game! @richleitch47 @RDM_26 @DuncanWatt19 @ding3722 @PrepBaseballON @JoshArcePB @CamAraujoPB

Pre-season clips. Timely triple in one game and 3 Ks over 2 innings in another. @TorontoMets @CPBLeague @richleitch47 @RDM_26 @DuncanWatt19 @ding3722 @PrepBaseballON @JoshArcePB @CamAraujoPB

In a patient with metastatic cervical cancer treated with the nectin-4–targeted antibody–drug conjugate bulumtatug fuvedotin, a new hepatic lesion proved to be pseudoprogression and resolved with continued therapy. Read the full case details: nejm.org/doi/full/10.1056/NE…

𝐎𝐧𝐭𝐚𝐫𝐢𝐨 𝐅𝐮𝐭𝐮𝐫𝐞 𝐆𝐚𝐦𝐞 𝐓𝐫𝐢𝐚𝐥𝐬 SS/RHP Rohan Persad 2027, @TorontoMets @PB_Uncommitted 5-foot-11, 180-pounds. Peak EV - 89.3 mph Max Dist - 320 feet Sweet Spot % - 53 Hand Speed Avg/Max - 18.6/20.1 Bat Speed Avg/Max - 67.2/71.5 Rotational Acc Avg/Max - 16.4/21.1 INF Velo - 90 mph @RoShowBaseball | #FGT26🇨🇦

"Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life." In #APieceofMyMind, a psychiatrist and residency program director reflects on an unexpected #LungCancer diagnosis. ja.ma/48OxHxC

𝐎𝐧𝐭𝐚𝐫𝐢𝐨 𝐅𝐮𝐭𝐮𝐫𝐞 𝐆𝐚𝐦𝐞 𝐓𝐫𝐢𝐚𝐥𝐬 SS/RHP Rohan Persad 2027, @TorontoMets @PB_Uncommitted 5-foot-11, 180-pounds. FB 80-82 | 9.3 IVB | 4 HB SL 69-71 | -8.6 IVB | -16.1 HB CH 70-72 | 14.8 IVB | 10.8 HB @RoShowBaseball | #FGT26🇨🇦

A few highlights from Spring training in #Florida @RussMattFL with @TorontoMets @CPBLeague Clip 1- Double to force a mercy Clips 2,3 - Pitched a scoreless 5 innings to help secure a W. @RDM_26 @DarrylReid2066 @schachow @richleitch47 @DuncanWatt19 @ding3722 @dbails20

Not sure why Sportsnet hasn't posted it, but an unbelievable opening montage

A season we’ll never forget 🫶

It's #OpeningDay for the #BlueJays50 ! Here's "All These Things That I've Done" by The Killers to get you set. @Sportsnet @BlueJays

This is incredible The Blue Jays celebrate 50 years of history 🇨🇦